- Home
- Products
Tazverik (Tazemetostat)
Tazverik (Tazemetostat)
- Medicine Name: Tazverik
- Generic Name: Tazemetostat
- Dosage Form & Strength: Tablets – 200 mg
- Manufactured By: Epizyme, Inc.
Tazverik is a methyltransferase inhibitor approved for:
- Adults and patients (≥16 years) with metastatic or locally advanced epithelioid sarcoma not eligible for surgical resection
- Adults with relapsed/refractory follicular lymphoma:
With EZH2 mutation after two prior systemic therapies
Without satisfactory alternative treatment options
Recommended Dosage:
- 800 mg orally twice daily (total daily dose: 1600 mg)
- Swallow tablets whole – do not chew, cut, or crush
- Can be taken with or without food
- If a dose is missed or vomiting occurs, skip and resume at the next scheduled dose
Secondary Malignancies: Patients should be monitored long-term for development of other cancers
Fetal Harm Risk: Use effective contraception during treatment and:
Females: For 6 months after the final dose
Males: For 3 months after the final dose (with female partners of reproductive potential)
- Breastfeeding: Avoid during and for 1 week after final dose due to potential serious risks to infants
Required Documents to Import Tazverik to India:
- Valid prescription from a licensed oncologist or specialist
- Diagnostic reports supporting the condition
- Government-issued photo ID of the patient
Order Confirmation:
Processed only after submission of all required documents and import permit (if applicable)
Availability:
Tazverik is available via Global Rare Meds in all major Indian cities including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Pune, Kolkata, Ahmedabad and more. Also available for international export under Named Patient Program.
To Order / Enquire Price:
- Call/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Tazverik from reliable manufacturers in the USA, Canada, Europe, and Australia. We ensure:
- Full legal compliance
- Verification by licensed pharmacists
- Dispatch from our Fulfillment Center in Ambernath, Thane District
- Fast and secure international or domestic delivery
What is the generic name of Tazverik®?
Tazemetostat
Who manufactures Tazverik®?
Epizyme, Inc.
Is Tazverik® FDA approved?
Yes, approved on January 23, 2020
What does Tazverik® treat?
Epithelioid Sarcoma (≥16 years) and relapsed/refractory Follicular Lymphoma in adults
What dosage forms are available?
Tablets: 200 mg
What are the most common side effects?
- Epithelioid Sarcoma: Pain, nausea, appetite loss, fatigue, vomiting, constipation
- Follicular Lymphoma: Abdominal pain, fatigue, upper respiratory tract infections, musculoskeletal pain, nausea
How should Tazverik be stored?
Store below 30°C (86°F). Keep out of reach of children.
Is it safe to buy Tazverik online in India?
Yes, Global Rare Meds offers authentic and legal access to Tazverik under the Named Patient Import Program
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
